Subcutaneous Immunotherapy for Cockroach (SCITCO)
Status: | Archived |
---|---|
Conditions: | Allergy, Asthma |
Therapuetic Areas: | Otolaryngology, Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Start Date: | September 2010 |
End Date: | August 2012 |
A Biomarker-Based Pilot Study of Cockroach Subcutaneous Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis
Scientific evidence has shown that, over the past two decades, the combination of cockroach
allergy and cockroach exposure is one of the most important factors contributing to the
dramatic increase in asthma morbidity seen in inner city children with asthma. Therefore, a
major goal of the Inner City Asthma Consortium is to evaluate the efficacy of cockroach
immunotherapy in inner city asthma. This trial is a pilot study of the safety of cockroach
subcutaneous immunotherapy (SCIT) in adults who have a history of perennial allergic
rhinitis, asthma, or both, and are cockroach sensitive.
We found this trial at
1
site
Johns Hopkins Hosp From the 1889 opening of The Johns Hopkins Hospital, to the opening...
Click here to add this to my saved trials